GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis

Aditya A. Joshi, Joseph B. Lerman, Tsion M. Aberra, Mehdi Afshar, Heather L. Teague, Justin A. Rodante, Parasuram Krishnamoorthy, Qimin Ng, Tarek Z. Aridi, Taufiq Salahuddin, Balaji Natarajan, Benjamin N. Lockshin, Mark A. Ahlman, Marcus Y. Chen, Daniel J. Rader, Muredach P. Reilly, Alan T. Remaley, David A. Bluemke, Martin P. Playford, Joel M. GelfandNehal N. Mehta

Research output: Contribution to journalArticlepeer-review

Abstract

Rationale: GlycA, an emerging inflammatory biomarker, predicted cardiovascular events in population-based studies. Psoriasis, an inflammatory disease associated with increased cardiovascular risk, provides a model to study inflammatory biomarkers in cardiovascular disease (CVD). Whether GlycA associates with psoriasis and how it predicts subclinical CVD beyond high-sensitivity C-reactive protein in psoriasis is unknown. Objective: To investigate the relationships between GlycA and psoriasis and between GlycA and subclinical CVD. Methods and Results: Patients with psoriasis and controls (n=412) participated in a 2-stage study. We measured GlycA by nuclear magnetic resonance spectroscopy. National Institutes of Health (NIH) participants underwent 18-F Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18-FDG PET/CT) scans to assess vascular inflammation (VI) and coronary computed tomographic angiography to quantify coronary artery disease burden. Psoriasis cohorts were young (mean age=47.9), with low cardiovascular risk and moderate skin disease. high-sensitivity C-reactive protein and GlycA were increased in psoriasis compared with controls (GlycA: [PENN: 408.8±75.4 versus 289.4±60.2, P<0.0001; NIH: 415.8±63.2 versus 346.2±46, P<0.0001]) and demonstrated a dose-response with psoriasis severity. In stage 2, VI (β=0.36, P<0.001) and coronary artery disease (β=0.29, P=0.004) associated with GlycA beyond CV risk factors in psoriasis. In receiver operating characteristic analysis, GlycA added value in predicting VI (P=0.01) and coronary artery disease (P<0.01). Finally, initiating anti-tumor necrosis factor therapy (n=16) reduced psoriasis severity (P<0.001), GlycA (463.7±92.5 versus 370.1±78.5, P<0.001) and VI (1.93±0.36 versus 1.76±0.19, P<0.001), whereas GlycA remained associated with VI (β=0.56, P<0.001) post treatment. Conclusions: GlycA associated with psoriasis severity and subclinical CVD beyond traditional CV risk and high-sensitivity C-reactive protein. Moreover, psoriasis treatment reduced GlycA and VI. These findings support the potential use of GlycA in subclinical CVD risk assessment in psoriasis and potentially other inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)1242-1253
Number of pages12
JournalCirculation research
Volume119
Issue number11
DOIs
StatePublished - Nov 11 2016

Keywords

  • FDG PET CT
  • GlycA
  • cardiovascular disease
  • coronary artery disease
  • inflammation
  • psoriasis
  • risk factors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis'. Together they form a unique fingerprint.

Cite this